Could a Two-Drug HIV combo protect babies without extra side effects?

NCT ID NCT00424814

Completed Prevention Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a simpler HIV drug combination (lopinavir/ritonavir alone) could safely prevent mothers from passing HIV to their babies during pregnancy, compared to the standard three-drug combo. About 105 pregnant women with well-controlled HIV took part. The goal was to see if the simpler regimen could keep virus levels low enough to protect the baby while reducing drug side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lopinavir/ritonavir (Kaletra) with or without zidovudine/lamivudine (Combivir)
What this could lead to: If successful, this could offer a safer, simpler way to prevent HIV transmission from mother to child during pregnancy, reducing drug side effects for both.
What could go wrong: This is a small, early-phase study (105 participants) that may not prove generalizable. The simpler regimen might not suppress the virus as well as standard combinations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

Hopital Pitie salpetriere

Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.